Major Late-Breaking Trials from EuroPCR 2024

Anchorperson: B. Prendergast

Spokesperson: T. Cuisset

Summary

This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis, and early outcomes of a randomised non-inferiority trial comparing TAVI devices. The session includes short methodology insights, discussions, and exploration of the impact on clinical practice.

Presentations available when logged in:

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II
Short methodology insight
Impact in practice
First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2
Short methodology insight
Impact in practice
Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
Short methodology insight
Impact in practice

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Major Late-Breaking Trials from EuroPCR 2024

Log in or create account for free